gabapentin has been researched along with Stomatitis in 6 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
Stomatitis: INFLAMMATION of the soft tissues of the MOUTH, such as MUCOSA; PALATE; GINGIVA; and LIP.
Excerpt | Relevance | Reference |
---|---|---|
"The addition of venlafaxine to prophylactic gabapentin did not result in improvements in pain control and quality of life among patients with head and neck cancer." | 9.69 | Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial. ( Attwood, K; Farrugia, M; Hermann, G; Iovoli, AJ; Ma, SJ; Neimanis, D; Singh, AK; Smith, KA; Wang, K, 2023) |
"The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement." | 9.51 | Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022) |
"HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
"To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck." | 9.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
"This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
"The addition of venlafaxine to prophylactic gabapentin did not result in improvements in pain control and quality of life among patients with head and neck cancer." | 5.69 | Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial. ( Attwood, K; Farrugia, M; Hermann, G; Iovoli, AJ; Ma, SJ; Neimanis, D; Singh, AK; Smith, KA; Wang, K, 2023) |
"The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement." | 5.51 | Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022) |
"HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
"To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck." | 5.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
"This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 3 (50.00) | 2.80 |
Authors | Studies |
---|---|
Cook, A | 1 |
Modh, A | 1 |
Ali, H | 1 |
Sheqwara, J | 1 |
Chang, S | 1 |
Ghanem, T | 1 |
Momin, S | 1 |
Wu, V | 1 |
Tam, S | 1 |
Money, S | 1 |
Han, X | 1 |
Fakhoury, L | 1 |
Movsas, B | 1 |
Siddiqui, F | 1 |
Ma, SJ | 1 |
Iovoli, AJ | 1 |
Wang, K | 1 |
Neimanis, D | 1 |
Smith, KA | 1 |
Attwood, K | 1 |
Farrugia, M | 1 |
Hermann, G | 1 |
Singh, AK | 2 |
Ala, S | 1 |
Zamani, N | 1 |
Akbari, J | 1 |
Salehifar, E | 1 |
Janbabai, G | 1 |
Koulaeinejad, N | 1 |
Kataoka, T | 1 |
Kiyota, N | 1 |
Shimada, T | 1 |
Funakoshi, Y | 1 |
Chayahara, N | 1 |
Toyoda, M | 1 |
Fujiwara, Y | 1 |
Nibu, K | 1 |
Komori, T | 1 |
Sasaki, R | 1 |
Mukohara, T | 1 |
Minami, H | 1 |
Milazzo-Kiedaisch, CA | 1 |
Itano, J | 1 |
Dutta, PR | 1 |
Sharp, H | 1 |
Morris, JC | 1 |
Van Waes, C | 1 |
Gius, D | 1 |
Cooley-Zgela, T | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma[NCT03269344] | Phase 3 | 65 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
A Pilot Phase I Dose Escalation Study Of The EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined With Paclitaxel (Taxol) And External Beam Radiation Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN)[NCT00083057] | Phase 1 | 30 participants (Anticipated) | Interventional | 2004-05-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT03269344)
Timeframe: Over the entire study period from baseline to follow-up, approximately 13 weeks
Intervention | Daily morphine equivalents (Median) |
---|---|
Control Arm | 15.6 |
Experimental Arm | 22.2 |
Scale: Patient-reported outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE), 5-point Likert scale, higher scores indicate worse outcomes. Range of scores 0-40 (min-max). (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks
Intervention | units on a scale (Median) |
---|---|
Control Arm | 1.0 |
Experimental Arm | 6.5 |
Scale tile: Patient Reported Oral Mucositis Symptoms scale, range 0-1000, higher scores indicate worse outcomes (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks
Intervention | score on a scale (Mean) |
---|---|
Control Arm | 20.1 |
Experimental Arm | 29.1 |
Scale: Functional Assessment of Cancer Therapy-Trial Outcome (FACT-HN), range 0-148, higher scores indicate better outcomes (NCT03269344)
Timeframe: Administered at baseline and at 6-week follow-up endpoint, approximately 13 weeks
Intervention | units on a scale (Median) |
---|---|
Control Arm | -15.0 |
Experimental Arm | -20.0 |
Measure of number of patients who required feeding tube placement at any time during the study period (NCT03269344)
Timeframe: Evaluated placement of feeding tube from baseline (start of radiation) to 6 weeks post-treatment, approximately 13 weeks
Intervention | Participants (Count of Participants) |
---|---|
Control Arm | 6 |
Experimental Arm | 18 |
Percent weight lost from baseline to week 7 of treatment (end of treatment) (NCT03269344)
Timeframe: Percent change from baseline to week 7 of treatment
Intervention | Percent change (Median) |
---|---|
Control Arm | -10.7 |
Experimental Arm | -11.4 |
1 review available for gabapentin and Stomatitis
Article | Year |
---|---|
Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
5 trials available for gabapentin and Stomatitis
Article | Year |
---|---|
Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
Topics: Double-Blind Method; Gabapentin; Head and Neck Neoplasms; Humans; Pain; Quality of Life; Squamous Ce | 2022 |
Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial.
Topics: Analgesics, Opioid; Gabapentin; Head and Neck Neoplasms; Humans; Mucositis; Pain; Quality of Life; S | 2023 |
Efficacy of gabapentin mouthwash in managing oral mucositis pain in patients undergoing chemotherapy: a prospective, randomised, double-blind, controlled clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents; Double-Blind Method; Female; Gaba | 2020 |
Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Carcinoma | 2016 |
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.
Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2008 |